Drugs / JSKN016
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07475559 | Mar 2026 → Jul 2028 expected | — | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06868732 | Apr 2025 → Jun 2028 expected | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06592417 | Apr 2024 → May 2026 overdue | cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07336771 | Jan 2026 → Dec 2027 expected | breast cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06942234 | Jun 2025 → Jun 2027 expected | Her2-receptor negative breast cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07493980 | Mar 2026 → Jan 2027 expected | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06775483 | Jan 2025 → Jun 2027 expected | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07533123 | Mar 2026 → Mar 2029 expected | triple-negative breast carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JSKN016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493980 ↗ |
| Known as | JSKN016 injection | “Drug: JSKN016 injection” NCT06592417 ↗ |
| Route | Intravenous | “8 mg/kgmg/kg, IV ,Q3W” NCT06592417 ↗ |